FN3.F Racura Oncology Ltd
- Market cap
- EUR 193M
- P/E
- -
- P/B
- 7.47x
- ROE
- -30.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is FN3.F undervalued?
Graham numberThe Graham number of Racura Oncology Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Racura Oncology Ltd fundamental analysis
No fundamental analysis for Racura Oncology Ltd yet.
Racura Oncology Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Racura Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and change…
Full company profileRacura Oncology Ltd financial statements
Racura Oncology Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating Income | -12.0M | -13.6M | -18.7M | -10.8M | -13.4M |
| EBITDA | - | -13.4M | -18.4M | -10.5M | -13.1M |
| Net Income | -11.2M | -9.92M | -13.8M | -4.79M | -11.1M |
| EPS | -0.07 | -0.06 | -0.08 | -0.03 | -0.06 |
| Balance Sheet | |||||
| Total Assets | 37.5M | 26.6M | 20.2M | 17.5M | 38.1M |
| Total Liabilities | 1.42M | 1.15M | 1.92M | 1.48M | 1.64M |
| Shareholders' Equity | 36.1M | 25.5M | 18.3M | 16.0M | 36.4M |
| Cash & Short-term Investments | 33.5M | 21.5M | 17.2M | 13.7M | 34.3M |
| Cash Flow | |||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 3.67K |
| Free Cash Flow | -6.26M | -10.7M | -9.55M | -4.57M | -8.25M |
| Ratios | |||||
| ROE | -31.0% | -38.9% | -75.5% | -29.9% | -30.4% |
| ROA | -29.9% | -37.3% | -68.3% | -27.4% | -29.1% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Racura Oncology Ltd dividends
Racura Oncology Ltd has not paid dividends in the last 6 fiscal years.
Who owns Racura Oncology Ltd
- Insiders 27.08%
- Institutions 0.10%
- Public & others 72.82%
- Shares outstanding 196M
- Free float 136M
Racura Oncology Ltd company profile
- Company name
- Racura Oncology Ltd
- Ticker
- FN3.F
- ISIN
- AU000000RAC3
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000
- Phone
- 61 2 8051 3043
- Website
- racuraoncology.com
About Racura Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Racura Oncology Ltd management
6- Dr. Peter Michael Smith Ph.D.Executive Chairman · born 1963
- Dr. Daniel TillettCEO, MD & Director
- Mr. Brendan BrownChief Financial Officer
- Dr. Sophia MoscovisVice President of Operations & Strategy
- Dr. Jose L. Iglesias M.D.Chief Medical Officer · born 1957
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963